Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604753 | 0.96 | SLC18A3 (0.49) | SLC18A3ARGRIA4HTR2AHTR2C | |
| SCHEMBL4604755 | 0.96 | SLC18A3 (0.49) | SLC18A3ARGRIA4HTR2AHTR2C | |
| SCHEMBL4604751 | 0.96 | SLC18A3 (0.49) | SLC18A3ARGRIA4HTR2AHTR2C | |
| SCHEMBL11476408 | 0.82 | SLC18A3 (0.45) | SLC18A3GRIA4HTR2AHTR2CHTR2B | |
| SCHEMBL10486574 | 0.81 | ESR2 (0.47) | SLC18A3ARCYP3A4CYP2C9 | |
| SCHEMBL16883880 | 0.81 | ESR2 (0.47) | SLC18A3ARCYP3A4CYP2C9 | |
| SCHEMBL5557513 | 0.79 | AR (0.40) | SLC18A3ARALDH1A1 | |
| SCHEMBL8724940 | 0.79 | KDM1A (0.47) | SLC18A3ARGRIA4HTR2CHTR2B | |
| SCHEMBL5562442 | 0.79 | SLC18A3 (0.53) | SLC18A3ARGRIA4HTR2AHTR2C | |
| SCHEMBL7995103 | 0.79 | SLC18A3 (0.53) | SLC18A3ARCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300886-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| CN-115190815-B | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4358946-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272174-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4081301-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115190815-A | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7173133-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1720873-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-1678177-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005068463-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300886-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | SLC18A3 58/4885AR 1533/4885GRIA4 53/4885 |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | HTR2C, PNMT, HTR2A | SLC18A3 60/4885AR 1606/4885GRIA4 51/4885 |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | GRIN1, GRIN2A, GRM1 | SLC18A3 169/4885AR 1364/4885GRIA4 7/4885 |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | SLC18A3 62/4885AR 2247/4885GRIA4 50/4885 |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HCN3, SCN3A, SLC6A3 | SLC18A3 955/4885AR 648/4885GRIA4 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.